Join our daily newsletter At The Bell to receive exclusive market insights
- Hitiq (HIQ) sells 200 Nexus Head Impact Sensors to Monash University in Melbourne to investigate the effects of head impacts on Australian Football players
- The sensor will be worn by sub-elite male and female AFL players in a multi-year project research program carried out by Monash University
- Monash plans to develop an artificial intelligence (AI) model for the Nexus sensors to translate HITIQ’s head impact data into a quantified risk of concussion
- The revenue to be generated under the Monash deal represents around 15 per cent of HITIQ’s operating revenues reported over its 2022 financial year
- HIQ shares are trading at 2.7 cents at 3:07 pm AEDT
Hitiq Limited (HIQ) has sold 200 Nexus Head Impact Sensors to Monash University in Melbourne to investigate the effect of head impacts on Australian football players.
The HITIQ Nexus head impact sensors will be worn by sub-elite male and female AFL players in a multi-year project research program carried out by Monash University.
The program aims to quantify head impact exposure in both genders and examine the relationship between impact exposure and blood biomarkers of Neuropathology.
The HITIQ technology also assesses the association between head impact exposure and changes in brain white matter integrity.
Monash University plans to pioneer the development of an artificial intelligence (AI) model for the Nexus sensors to translate HITIQ’s head impact data into a quantified risk of concussion.
The revenue to be generated between the HIQ/Monash agreement represents approximately 15 per cent of HITIQ’s operating revenues reported over the 2022 financial year.
“We are excited to collaborate with a world-class research team led by Stu
McDonald,” HITIQ CEO Mike Vegar said.
“A key objective for HITIQ moving forward is increasing data capabilities
through developing methods to transform our data from descriptive to predictive.
“Utilising artificial Intelligence methodologies, we believe, is the future of prediction,
and we are eager to be engaging in this space.”
HITIQ retains exclusive first rights of refusal on any IP or commercial products developed out of the research program derived from the HITIQ technology.
HIQ shares were trading at 2.7 cents at 3:07 pm AEDT.
